Document is current
Any future updates will be listed below
-
Authors
Li, Shanshan
Fu, Xufeng
Wang, Junfeng
Yang, Hongju
Wang, Dan
Dong, Xudong
Duan, Yanchao
Wang, Hong
Yan, Yaping
-
Funding
Funding for this research was provided by:
National Key Research and Development Program of China (2018YFA0801400)
Natural Science Foundation of Yunnan Province (202202AG050018)
Yunnan Provincial Key Research and Development Plan (202403AC100020)
Famous Medical Specialist of High-level Talent Training Support Program of Yunnan Province (RLMY20190004)
Yunnan Health Training Project of High Level Talents (L-2019016)
Yunnan High-level Talent Cultivation Support Plan of Famous Doctor Project (KH-SWR-MY-2020-001)
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 10 September 2024
First Online: 19 September 2024
Declarations
:
: All animal work was compliant with the protocol of Institutional Animal Care and Use Committees (IACUC) at Kunming University of Technology (PZWH-K2019-0007). Date of approval is Jan 2, 2020. Title of the approved project: Therapeutic efficacy and distribution of human umbilical cord-derived mesenchymal stem cell spheroids transplanted via the portal vein into rhesus monkey models of liver fibrosis. Usage of human sample (<i>n</i> = 3, from healthy donors) and the protocol used in this study are approved by Ethics Committee of Yunnan first people’s Hospital (KHLL2019-KY052). Date of approval is Dec 25, 2019. All the donors (<i>n</i> = 3) provided informed consents prior to tissue donation. Title of the approved project: Establishment of key clinical applicability technologies for MSCs derived from human umbilical cord and application in the treatment of liver fibrosis in macaques.
: Not applicable.
: The authors have declared that no competing interest exists.
